Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK5TWM2OD13Lki2OlYh|ryP NF7SXndUSU6JRWK=
DOHH-2 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\pZmgyUUN3ME25MlM2Pjh7IN88US=> M{H0WnNCVkeHUh?=
no-10 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Wyb2lEPTB;OT65NFM6KM7:TR?= MXfTRW5ITVJ?
LS-513 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPzTJNlUUN3ME2xNU4{PTR5IN88US=> NX\yd5h6W0GQR1XS
ALL-PO MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO5S4d5UUN3ME2xNU44PzN2IN88US=> NYjVNZdEW0GQR1XS
8-MG-BA NFXET2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXue5JKSzVyPUGzMlEyOjNizszN M17rPHNCVkeHUh?=
RPMI-8402 M4PKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXLTWM2OD1zNT64OVM4KM7:TR?= MVXTRW5ITVJ?
EoL-1-cell M1\BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF6LkW5OFgh|ryP NVzqSo9KW0GQR1XS
NALM-6 M2HwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLxTWM2OD1zOT6wNVY4KM7:TR?= NWfyWoY3W0GQR1XS
DEL M1;qO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P2V2lEPTB;MkCuNVQ4OSEQvF2= NUnmN21tW0GQR1XS
SR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\hTWM2OD1{Mz62O|E2KM7:TR?= MkPFV2FPT0WU
697 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsTWM2OD1{Nj62NVU2KM7:TR?= NUO4cWZHW0GQR1XS
COLO-829 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr1TZRKSzVyPUK2Mlg1QDNizszN NXHn[FJTW0GQR1XS
EVSA-T NFP6[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ5LkW1OlEh|ryP M123cHNCVkeHUh?=
ATN-1 M3;SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLxeYJQUUN3ME2zNU4zOzJ7IN88US=> NEexVHJUSU6JRWK=
L-363 M3roSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnwTWM2OD1|MT63OFYyKM7:TR?= NWfZ[IZCW0GQR1XS
LAMA-84 NGDQOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzYSZpYUUN3ME2zNk42OjFzIN88US=> NFnTV5RUSU6JRWK=
NOS-1 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PTPWlEPTB;M{SuNlk2PiEQvF2= NV;xelZtW0GQR1XS
BB30-HNC M{PjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X4VGlEPTB;M{SuN|MxPiEQvF2= MnT0V2FPT0WU
BC-1 M2Dye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[2dmlEPTB;M{euPVc1PiEQvF2= MV7TRW5ITVJ?
IST-SL2 M4\3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELqPIdKSzVyPUO4MlIzPCEQvF2= NIGzbJBUSU6JRWK=
D-392MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXOTWM2OD12MD6yNlE2KM7:TR?= MUHTRW5ITVJ?
no-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLNTWM2OD12MD61OVIyKM7:TR?= NF:2TphUSU6JRWK=
LC4-1 NV7zOppnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTTTWM2OD12MD64O|E3KM7:TR?= NE\5fI1USU6JRWK=
A388 NHu0PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnTSJhQUUN3ME20Nk42QDR6IN88US=> MVjTRW5ITVJ?
NTERA-S-cl-D1 NIr2SphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7rTWM2OD12Mj63NFc1KM7:TR?= NETVW|NUSU6JRWK=
CESS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnLb|FVUUN3ME20OE4zOjN{IN88US=> NUPVfmxYW0GQR1XS
RS4-11 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXCdYpKSzVyPUS5MlA6OzhizszN MmjhV2FPT0WU
MS-1 NGPnTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0eWlEPTB;NUCuPVM2OSEQvF2= NHfKW2hUSU6JRWK=
CTV-1 NI\mOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nqVmlEPTB;NUGuNFc1KM7:TR?= NIfpUXpUSU6JRWK=
D-502MG NWTDTGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnqOm1FUUN3ME21NU43OjdzIN88US=> NW[wWnlXW0GQR1XS
ML-2 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KOXdmUUN3ME21Nk46OTl3IN88US=> MVvTRW5ITVJ?
SK-NEP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\meIpKSzVyPUWzMlM6OjNizszN MVPTRW5ITVJ?
LOXIMVI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTV|LkW4PFQh|ryP NIfCfmhUSU6JRWK=
DJM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTV4LkOzPVEh|ryP NXraNGltW0GQR1XS
GI-1 NVPoNYxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr5XpJEUUN3ME21Ok43OTR7IN88US=> NVTreo5KW0GQR1XS
IST-MES1 NGj0e5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zhdGlEPTB;NkCuOVQ6OyEQvF2= M3uxSnNCVkeHUh?=
MV-4-11 NEDrVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXGTWM2OD14MD62OVM5KM7:TR?= MmXBV2FPT0WU
OVCAR-4 M{Laemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD14Mz61OlU4KM7:TR?= NH3SN2pUSU6JRWK=
KE-37 NYP5RldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDDcVZKSzVyPU[2MlI3PjhizszN NVfZT2x4W0GQR1XS
D-542MG MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLrTWM2OD14OD60NVM2KM7:TR?= NW\TPZBoW0GQR1XS
MHH-PREB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWniU3k6UUN3ME23Nk45PDRzIN88US=> NVm3V4xRW0GQR1XS
MRK-nu-1 NHXpeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qzdWlEPTB;N{OuOFcxPSEQvF2= NEf6N3lUSU6JRWK=
D-247MG MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX2SHM6UUN3ME23N{42PDR{IN88US=> MmjUV2FPT0WU
OCI-AML2 M1jpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PySmlEPTB;N{[uPVM3QSEQvF2= NVTmPYZKW0GQR1XS
LP-1 M3vHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jVdWlEPTB;OEKuPFc{OSEQvF2= NELicVRUSU6JRWK=
HCC1599 NI\o[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnnSG5lUUN3ME24OE4zQDN5IN88US=> MofrV2FPT0WU
KARPAS-45 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTh2Lk[5PVIh|ryP NY[5U|FmW0GQR1XS
BE-13 NEnyV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX5ZoxKSzVyPUm5MlA1PzdizszN M4fVW3NCVkeHUh?=
GCIY MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTIbFVKSzVyPUm5MlA6PTRizszN MUDTRW5ITVJ?
BV-173 NXrG[mFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHRW49KSzVyPUGwNE4{OjVizszN NIPxWYNUSU6JRWK=
LB2518-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFyMD63PFkh|ryP NVLoZ3l2W0GQR1XS
KS-1 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkewTWM2OD1zMEGuOlM6KM7:TR?= M1j1bXNCVkeHUh?=
MOLT-16 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuxc4xKSzVyPUGwOE46QDZizszN M3v2THNCVkeHUh?=
NCI-H1770 NUPMSpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFyOD63PFQh|ryP NX3hfms3W0GQR1XS
NCI-H82 M3vG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHoVmhGUUN3ME2xNVAvQTd4IN88US=> M1LvO3NCVkeHUh?=
NCCIT MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[3OWlEPTB;MUGyMlUzQSEQvF2= MlLXV2FPT0WU
KALS-1 NIDVd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\BOmlEPTB;MUG1Mlk1OSEQvF2= MWXTRW5ITVJ?
LB2241-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XFdmlEPTB;MUG2MlY4QSEQvF2= NFzSRm5USU6JRWK=
HH Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFzNz6zPVUh|ryP M13MPXNCVkeHUh?=
HD-MY-Z MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFzOD60PFgh|ryP M2XwTHNCVkeHUh?=
EB-3 M{TXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO5RZVKSzVyPUGyN{4xQTRizszN NGPLPGtUSU6JRWK=
BL-70 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTK[XVKSzVyPUGyN{4yOjdizszN NV;kfmI4W0GQR1XS
K-562 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fVNWlEPTB;MUK2MlI1PSEQvF2= M2fPNHNCVkeHUh?=
HT-144 NFfTRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHUSI9RUUN3ME2xN|MvOTZ2IN88US=> NFnDZ5JUSU6JRWK=
PF-382 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:zd2lEPTB;MUO0MlM3OSEQvF2= M{PPRnNCVkeHUh?=
RPMI-8226 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\iWWlEPTB;MUO1MlA1PSEQvF2= MoTVV2FPT0WU
NCI-H1355 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF|NT61PFch|ryP NH7x[JNUSU6JRWK=
LXF-289 M4nyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF|OT63PFEh|ryP NFvBNmNUSU6JRWK=
NCI-H69 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HWWWlEPTB;MUSyMlk{OiEQvF2= Mo\MV2FPT0WU
SK-MEL-1 NWLKb444T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF2Nz6xN{DPxE1? NUXOS|lUW0GQR1XS
KARPAS-299 NHXwcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ewN2lEPTB;MUS5MlEzKM7:TR?= MVXTRW5ITVJ?
GB-1 NY\PO|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLNTWM2OD1zNEmuN|IzKM7:TR?= MXrTRW5ITVJ?
CMK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3WTWM2OD1zNEmuOVE2KM7:TR?= Ml7vV2FPT0WU
MPP-89 M3jGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPFTWM2OD1zNU[uNFM2KM7:TR?= MnLwV2FPT0WU
KU812 NYLLOYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjFZWhvUUN3ME2xOlEvQTB{IN88US=> NVfD[JJCW0GQR1XS
REH NW\OW2tVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzXOlJFUUN3ME2xOlIvOTJ3IN88US=> NWrGb4xVW0GQR1XS
NEC8 NIW1ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF4NT6wNlYh|ryP MWfTRW5ITVJ?
KP-N-YS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL1fYE1UUN3ME2xOlgvOzl3IN88US=> MYTTRW5ITVJ?
Ramos-2G6-4C10 M1XCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\oRWlEPTB;MU[5MlkyPSEQvF2= MnHEV2FPT0WU
Becker NETLZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPYWJdJUUN3ME2xO|QvOThizszN MYDTRW5ITVJ?
LB647-SCLC NW\hSYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF5NT64OFUh|ryP NXvaW|hOW0GQR1XS
LU-139 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLMTWM2OD1zN{iuNFE6KM7:TR?= NU[1bGtRW0GQR1XS
QIMR-WIL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnlZVhKSzVyPUG3PU43PDZizszN M2D3WnNCVkeHUh?=
NCI-H1395 NGDJc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF5OT65PVYh|ryP NVrrdpZvW0GQR1XS
NOMO-1 NXvrTY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3RSJFKSzVyPUG4Nk45PSEQvF2= NHjC[5VUSU6JRWK=
GI-ME-N MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;MdGlEPTB;MUi3Mlk3QSEQvF2= MVHTRW5ITVJ?
KMS-12-PE MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P3TWlEPTB;MUi5MlI4OyEQvF2= NFnzNpBUSU6JRWK=
Daudi MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LuOmlEPTB;MUmxMlEzQCEQvF2= NU\aTYFLW0GQR1XS
LB996-RCC NXLKWph6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF7MT62PVkh|ryP Mnj6V2FPT0WU
NCI-H2107 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TvSmlEPTB;MUmzMlc{QSEQvF2= MW\TRW5ITVJ?
SK-PN-DW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrJe|JoUUN3ME2xPVQvPzF7IN88US=> NILxe3JUSU6JRWK=
MC-CAR NEm5XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDBU2dmUUN3ME2yNFIvOjV|IN88US=> MoPRV2FPT0WU
SNB75 M{fEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f6S2lEPTB;MkKxMlk1KM7:TR?= NFnoV3NUSU6JRWK=
ES4 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfHNW84UUN3ME2yNlMvPzh|IN88US=> NEftUG1USU6JRWK=
KARPAS-422 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDxTWM2OD1{MkiuN|UzKM7:TR?= MWLTRW5ITVJ?
NCI-H1648 M4[4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ{OT60PFkh|ryP Mnr1V2FPT0WU
ES6 NFTY[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG4PGhKSzVyPUKzPU41OyEQvF2= M4jVV3NCVkeHUh?=
KNS-81-FD NIjGXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj5TWM2OD1{NEGuNVk4KM7:TR?= M3n0eXNCVkeHUh?=
JAR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ3Nj6yNlUh|ryP NWSyV4VzW0GQR1XS
NB1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ4MD61NVYh|ryP M4DFZnNCVkeHUh?=
D-336MG NXuxOnV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fuWGlEPTB;Mk[wMlY6QCEQvF2= M{[0UHNCVkeHUh?=
BC-3 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ4NT6xO|gh|ryP NIDxVYhUSU6JRWK=
HCC2218 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD1{Nk[uOFE2KM7:TR?= NFPNTIJUSU6JRWK=
TE-9 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX0ZZlXUUN3ME2yOlYvPjJ5IN88US=> NYrs[5NRW0GQR1XS
LB1047-RCC NVjUcHhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn5WlhKSzVyPUK2Ok44PTNizszN MkDzV2FPT0WU
CTB-1 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\tTWM2OD1{NkmuPVc{KM7:TR?= NHnP[JNUSU6JRWK=
NB7 NUTUcYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WwfWlEPTB;MkexJO69VQ>? MVrTRW5ITVJ?
ST486 NYe4WJlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ5Nz60NVIh|ryP MVzTRW5ITVJ?
HCC1187 NHj1NJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\kZoxrUUN3ME2yPFIvQDFzIN88US=> MlrXV2FPT0WU
NCI-SNU-16 NFTDRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjKb2NqUUN3ME2yPFQvOjR6IN88US=> NX7kPGtGW0GQR1XS
COR-L279 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVNmlEPTB;MkmxMlU5PCEQvF2= M3HIUnNCVkeHUh?=
ES8 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPjTWM2OD1{OUSuNVgzKM7:TR?= NILjWG5USU6JRWK=
U-698-M NIXFZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O4NGlEPTB;Mkm4MlI1OyEQvF2= M4rnXnNCVkeHUh?=
HEL NHLSXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCxSYFKSzVyPUOwPU4yPDlizszN MlfSV2FPT0WU
KINGS-1 NU\aPYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe0PZUzUUN3ME2zNVAvPjd2IN88US=> NWDzNnBoW0GQR1XS
KY821 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjpUWdKSzVyPUOzOk42QTVizszN M{W2cnNCVkeHUh?=
MZ1-PC MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDiTWM2OD1|NEWuOlE5KM7:TR?= MkPrV2FPT0WU
LS-411N MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDlTWM2OD1|NUSuOlYh|ryP M4CwSnNCVkeHUh?=
SIG-M5 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN3OT63PFIh|ryP NUjYT244W0GQR1XS
HT MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTPTWM2OD1|NkeuO|EyKM7:TR?= NIW5XINUSU6JRWK=
HC-1 M3PRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fwXWlEPTB;M{[3Mlc5PyEQvF2= M{\rTXNCVkeHUh?=
NCI-H1694 M4C3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHGTWM2OD1|N{KuPVM1KM7:TR?= MVvTRW5ITVJ?
BB65-RCC NEX6RllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvsR4k2UUN3ME2zO|YvOjR3IN88US=> M2nac3NCVkeHUh?=
HAL-01 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEOwcIpKSzVyPUO3PU45OzhizszN NFvwOJRUSU6JRWK=
ARH-77 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHUSoFbUUN3ME2zPVQvODB6IN88US=> MWfTRW5ITVJ?
MZ7-mel MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfaNVNKSzVyPUO5O{4zOzNizszN NEnWcG9USU6JRWK=
SIMA M4DES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRyMz65N|Mh|ryP M1SwNnNCVkeHUh?=
DG-75 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Ecm03UUN3ME20NVUvPjl6IN88US=> NI\LOFRUSU6JRWK=
HUTU-80 NUfjWFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTTTWM2OD12MUmuNVg2KM7:TR?= M2rBZXNCVkeHUh?=
KNS-42 NILKT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;mPFRvUUN3ME20NlUvQDF3IN88US=> NVXlWXNIW0GQR1XS
SH-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTR{Nz61OlUh|ryP NGfZdllUSU6JRWK=
L-540 NXLzbpFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WwbGlEPTB;NEOxMlA{OSEQvF2= MYrTRW5ITVJ?
NB10 M1XzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPqdIc2UUN3ME20OFEvOjN2IN88US=> MYrTRW5ITVJ?
ES1 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkThTWM2OD12NUKuO|U{KM7:TR?= MojWV2FPT0WU
KMOE-2 M2nsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTMXIpKSzVyPUS1Ok44OTFizszN MnvmV2FPT0WU
MC116 M3LWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPyOotKSzVyPUS1PE4yOTZizszN NYnFNmFsW0GQR1XS
RCC10RGB NIjTTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\WOWVKUUN3ME20OlAvODB3IN88US=> MXzTRW5ITVJ?
RL95-2 NVvZSYFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLIfZRjUUN3ME20OlAvOjN5IN88US=> NILUPZJUSU6JRWK=
Raji MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHVTWM2OD12NkiuNVQ{KM7:TR?= MXzTRW5ITVJ?
CAS-1 NE\aVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7RTWM2OD12N{KuNFc{KM7:TR?= NVTHR4dIW0GQR1XS
Calu-6 M3W5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR5NT6yOlUh|ryP M1vhbHNCVkeHUh?=
KG-1 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\IXWFKSzVyPUS3PE41PCEQvF2= MVHTRW5ITVJ?
LB771-HNC M3PvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPFdnZmUUN3ME20PFIvOjN{IN88US=> MlzqV2FPT0WU
ACN NVLvRZVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DKTGlEPTB;NEmzMlU6QSEQvF2= MWLTRW5ITVJ?
KM12 NHPCUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jObWlEPTB;NEm2MlU5QSEQvF2= NHnHe2JUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID